Forte Biosciences (FBRX) Cash from Operations (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Cash from Operations data on file, last reported at 18808000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 18808000.0, down 81.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 59353000.0 (down 72.37% YoY), and the FY2025 annual result was 50900000.0, down 65.56% from the prior year.
• Cash from Operations fell to 18808000.0 in Q1 2026 per FBRX's latest filing, from 16484000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 1377000.0 in Q2 2022 and troughed at 18808000.0 in Q1 2026.
• A 5-year average of 8079058.82 and a median of 8133000.0 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 65.03% in 2022, then slumped 366.91% in 2023.
• A 5-year view of Cash from Operations shows it stood at 2893000.0 in 2022, then sank by 210.02% to 8969000.0 in 2023, then retreated by 11.6% to 10009000.0 in 2024, then tumbled by 64.69% to 16484000.0 in 2025, then declined by 14.1% to 18808000.0 in 2026.
• Business Quant data shows FBRX's Cash from Operations at 18808000.0 in Q1 2026, 16484000.0 in Q4 2025, and 14000000.0 in Q3 2025.